Breast cancer has variability from the different cell types with different patterns of gene expression in breast cancer, but a new study found that that variability should not be a barrier to using gene expression tests to help tailor cancer treatments to individual patients. These findings were presented at the 5th IMPAKT Breast Cancer Conference.
Among women with estrogen-receptor positive breast cancer, late recurrence was best predicted by the clinical treatment score. Significant prognostic value was added by the PAM50 risk of recurrence score and by the Breast Cancer Index score, according to a study comparing five scores that was presented at the 5th IMPAKT Breast Cancer Conference in Brussels, Belgium.
Women with breast cancer who had the strongest social relationships were likeliest to report fewer symptoms and the best overall quality of life.
Some patients with early breast cancer had a benefit in clinical response rate when everolimus was added to trastuzumab treatment, though the benefit was statistically nonsignificant. These puzzling results suggested that this benefit was independent of the molecular pathways that could be expected to be involved.
A new study shows a significant correlation between poorer performance on neuropsychological tests and memory complaints in posttreatment, early-stage breast cancer patients—particularly those who have undergone combined chemotherapy and radiation.
Aerobic exercise may reduce breast cancer risk by changing estrogen metabolism to produce more of the metabolites that keep the disease at bay.
A new retrospective study suggests that anti-HER2 treatments have anti-cancer effects in a small subset of patients with advanced non-small cell lung cancer who harbor specific mutations in the HER2 protein.
Drinking coffee could decrease the risk of breast cancer recurring in patients taking the widely used drug tamoxifen, according to a recent study.
Integrated 2-dimensional (2D) and 3-dimensional (3D) mammography improves the detection of breast cancer and reduces false-positive findings.
A breast cancer assay helped quantify the risk of recurrence after surgical excision for ductal carcinoma in situ (DCIS) without radiation.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|